Skip to main content Skip to section navigation Skip to footer
Capricor Therapeutics, Inc.
  • Home
  • About Us
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisors (DMD)
  • Our Science
    • Deramiocel (Biologic Medicine)
    • Exosomes Technology
    • Publications
    • Strategic Partnerships
  • Pipeline
    • Pipeline
    • Duchenne Muscular Dystrophy Overview
    • Clinical Trials
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • In the News
    • IR Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Overview
    • Leadership
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
    • Latest Proxy Statement and Annual Report
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity
  • News & Events

  • Overview
  • Press Releases
  • In the News
  • IR Calendar
  • Presentations
  • Email Alerts
Sep 07, 2021 9:00 am EDT

Capricor Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Sep 02, 2021 8:30 am EDT

Capricor Therapeutics to Present Final Data from HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society 2021

Aug 12, 2021 4:01 pm EDT

Capricor Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Aug 05, 2021 9:00 am EDT

Capricor Therapeutics to Present Second Quarter 2021 Financial Results and Recent Corporate Update on August 12

Aug 04, 2021 8:00 am EDT

Capricor Announces Joint Publication with the US Army Institute of Surgical Research for Cardiosphere-Derived Exosomes as a Potential Therapeutic for Shock

Jul 27, 2021 8:00 am EDT

Capricor Therapeutics Announces the Appointment of Karimah Es Sabar to its Board of Directors

Jun 17, 2021 9:00 am EDT

Capricor Therapeutics to Present Findings from HOPE-2 Open-Label Extension Study at Parent Project Muscular Dystrophy (PPMD) 2021 Virtual Annual Conference

Jun 10, 2021 9:15 am EDT

Capricor Therapeutics to Participate in BIO Digital 2021 Conference

May 18, 2021 8:30 am EDT

Capricor To Present Preclinical Data for Exosome-mRNA Vaccine for SARS-CoV-2 at the International Society for Extracellular Vesicles (ISEV) Annual Meeting

May 13, 2021 4:05 pm EDT

Capricor Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • Page 15
  • …
  • Page 32
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Company Profile
  • Contacts
  • RSS News Feed
  • Visit us on Linkedin
  • Visit us on Facebook
  • Visit us on Instagram
  • Visit us on Twitter
©2025 Capricor Therapeutics, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap Manage Cookie Preferences